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Abstract: Glatiramer acetate is an immunomodulating drug used in the treatment of multiple 
sclerosis. It consists of a copolymer of amino acid residues in the same stoichiometric propor-
tions as in myelin basic protein. Its mechanism of action is not entirely known and is probably 
multifaceted, with deletion of some immune cell populations and stimulation of others in these 
patients. Some mechanisms involve neuroprotectant effects. There is ample evidence of its 
efﬁ  cacy in relapsing-remitting disease, using both clinical and imaging measures of disease 
activity, and in this paper we review the clinical and basic studies of this drug. Finally we 
discuss how some of its neuroprotectant effects may be useful in neurodegeneration such as 
is seen in more advanced cases of multiple sclerosis and other diseases such as amyotrophic 
lateral sclerosis and Parkinson’s disease.
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Introduction
Multiple sclerosis (MS) is an inﬂ  ammatory demyelinating disease of the central nervous 
system (CNS), affecting separate regions of the brain and spinal cord at different times, 
with axonal damage. It is usually relapsing and remitting (RRMS), at least initially. The 
disease often enters a secondary progressive (SPMS) phase, with smoothly increasing 
deﬁ  cits, leading to substantial disability over time. In this phase of the disease, the 
pathogenesis is more “degenerative” than inﬂ  ammatory. It must be acknowledged 
that this is an oversimpliﬁ  cation and depends on deﬁ  ning the inﬂ  ammatory phase of 
RRMS as gadolinium enhancement of lesions on magnetic resonance imaging (MRI) 
T1 sequences, a marker of changes in the blood-brain barrier to humoral factors. Thus 
the lack of gadolinium enhancement would not rule out inﬁ  ltration of inﬂ  ammatory 
cells and it is known that using triple dose of gadolinium shows that many lesions 
thought not to enhance with a single dose still have blood-brain barrier defects. In 
addition the persistence of cerebrospinal ﬂ  uid (CSF) oligoclonal bands and the detection 
of inﬂ  ammatory cells in the brain and spinal cord of SPMS patients, in the absence of 
gadolinium enhancement, further supports a persistence of the inﬂ  ammatory component 
in the pathogenesis of MS lesions even during the “degenerative” phase of the course 
of the disease. A small proportion of cases are progressive at onset, and this is known 
as the primary progressive form of MS (PPMS). The term “chronic progressive” MS 
(CPMS) is an obsolete term encompassing SPMS, PPMS, and progressive relapsing 
MS (PRMS). More recently it has become clear that there are extensive changes in the 
gray matter including cerebral cortex and deep nuclear structures such as the thalamus 
and that these changes occur very early in the course of the disease. The mechanisms 
of these neuronal changes are not well understood and there are likely several of 
importance. Moreover the relationships between the pathogenic processes in white Neuropsychiatric Disease and Treatment 2007:3(2) 260
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matter with those seen in the gray matter are not clear (Kidd 
et al 1999; Peterson et al 2001; Kutzelnigg et al 2005) 
Glatiramer acetate (GA) is an immunomodulating agent 
approved by the FDA for the treatment of RRMS. The drug 
was originally prepared as an analog of myelin basic protein 
(MBP), and consists of a random copolymer of L-alanine, 
L-lysine, L-glutamic acid, and L-tyrosine, in a molar ratio 
4.2:3.4:1.4:1.0, respectively, as a string of 40–100 amino acid 
residues. The compound was used in research on experimen-
tal allergic encephalomyelitis (EAE), an animal model of MS, 
in which the injection of myelin antigens (whether puriﬁ  ed in 
adjuvant or crude extracts of white matter) triggers inﬂ  am-
matory demyelination, with some parallels to MS. The drug 
was found to strongly inhibit the inﬂ  ammatory demyelination 
which occurs in EAE (Arnon 1996). 
Clinical studies and trials
Open label studies
The success of GA in preventing and ameliorating EAE 
suggested its potential for beneﬁ  t in MS, and preliminary 
studies were initiated early on.
In the ﬁ  rst published report of the use of GA in humans, 
Abramsky et al (1977) gave GA to 3 patients with acute dis-
seminated encephalomyelitis (ADEM) (2 mg intramuscularly 
daily) and 4 patients with severe MS (2–3 mg intramuscularly 
every 2–3 days). The drug was well tolerated. 
An open label study of 12 patients with CPMS and 4 with 
RRMS examined the effect of GA given intramuscularly, origi-
nally intended to be given at decreasing doses over a 6-month 
period. However, there were hints of efﬁ  cacy and many of the 
patients continued the drug at doses of up to 20 mg a day, for 18 
months to more than 2 years. None of the patients deteriorated 
and a few seemed to improve (Bornstein et al 1981).
Controlled trials
In an important pilot trial of GA, 50 RRMS patients were 
divided into treatment and placebo groups, with patients in-
dividually matched for gender, relapse frequency and degree 
of disability before entering the study (Bornstein et al 1987). 
The degree of disability was measured by the Kurtzke ex-
tended disability status score (EDSS) (Kurtzke 1983). The 
treatment group received GA 20 mg daily for 2 years. The 
primary outcome variable was the proportion of relapse-free 
patients, while secondary outcomes consisted of frequency 
of exacerbations, change in disability and time free of pro-
gression. The results showed clear beneﬁ  t with GA. The 
proportions of relapse-free patients in the treatment and 
placebo groups were 56% and 26% (p = 0.045) respectively. 
The number of relapses in the treatment and placebo groups 
was 16 and 62. Interestingly, the less disabled patients had 
more beneﬁ  t in the relapse rate than the more disabled 
patients, in the treatment group, suggesting a greater ef-
ﬁ  cacy the earlier treatment is started (Tselis and Khan 
2004).
The next trial examined the efﬁ  cacy of GA in CPMS. In 
this study 106 “chronic progressive” patients, at 2 sites 
(Albert Einstein, Bronx, NY and Baylor, Houston, Texas), were 
randomized to either placebo or GA 15 mg twice daily for 2 
years (Bornstein et al 1991). The primary endpoint was the 
proportion of patients with conﬁ  rmed progression. Conﬁ  rmed 
progression was deﬁ  ned as a change in EDSS by 1.0 or 1.5 
steps (for those with baseline EDSS greater or less than 5.0 
respectively) sustained for 3 months. As previously stated, 
“chronic progressive” MS is not a homogeneous entity and 
included both SPMS and PPMS, which dilutes the patient 
groups and makes valid comparisons difﬁ  cult.
Overall, there was no statistically signiﬁ  cant (in the sense 
of p ≤ 0.05) difference in the primary outcome between the 
two groups at the 24 month time point. Interestingly, there 
was a trend (in the sense of 0.05 ≤ p ≤ 0.10) to beneﬁ  t from 
GA at both the 12- and 24-month time points, with progres-
sion in 20.4% of treatment and 29.5% of placebo subjects at 
two years, p = 0.086 (Bornstein et al 1991). When the results 
were analyzed by center, however, some interesting observa-
tions were made. At the Einstein site there was a statistically 
signiﬁ  cant beneﬁ  cial effect, with a probability of progression 
of 21.4% in treated patients and 38.5% in placebo patients, 
p = 0.041. At Baylor there was no difference, with 19% of 
both treated and placebo patients progressing. The placebo 
patients at Einstein had a much higher rate of progression 
(with 34% progressing) than the Baylor patients (only 14.8% 
progressing). The reason for this is unknown, but may have 
to do with the relative proportions of SPMS and PPMS 
patients at each center.
The pivotal trial, leading to the approval of GA by the 
Food and Drug Administration (FDA) for RRMS, consisted 
of 251 patients randomized to GA 20 mg subcutaneously 
once a day or placebo, for 24 months (Johnson et al 1995). 
The patients had EDSS scores between 0 and 5.0, at least 2 
relapses within the preceding 2 years, and no recent cortico-
steroid or immunomodulatory therapy. The primary endpoint 
was the mean number of relapses per patient during 2 years 
of treatment, with a comparison between the treatment and 
placebo patients. A number of secondary outcomes were 
studied, including proportion of patients relapse-free, time 
to ﬁ  rst relapse after initiation of therapy and proportion of Neuropsychiatric Disease and Treatment 2007:3(2) 261
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patients with progression (deﬁ  ned as a one step increase in 
the EDSS sustained for at least 3 months).
The results showed a statistically signiﬁ  cant decrease 
in relapse frequency, a trend to beneﬁ  t in delay to the next 
relapse and proportion of patients relapse-free and no sta-
tistically signiﬁ  cant effect on progression-free proportion. 
Thus, the GA group had 161 relapses and the placebo group 
210, giving an average number of relapses in 2 years of 1.19 
and 1.68, respectively, with p = 0.0007. The median time to 
ﬁ  rst relapse after enrollment was 287 and 198 days in the 
treatment and placebo groups (p = 0.097). The proportion of 
patients relapse-free was 33.6% and 27.0% in the treatment 
and placebo groups, respectively (p = 0.098). The proportion 
of patients progression-free was 78.4% and 75.4% in the 
treatment and placebo groups, respectively (NS).
The drug was well tolerated, causing insigniﬁ  cant injec-
tion site reactions. In about 15% of glatiramer patients and 
3% of placebo patients, a peculiar reaction occurred just after 
injection. This consisted of some combination of ﬂ  ushing, 
chest tightness, dyspnea, palpitations, or anxiety, lasting 
a few seconds to half an hour, and resolved without any 
residual problem. The reaction usually occurred only once, 
but one patient had seven episodes (Johnson et al 1995).
The extension study
In order to continue to collect data on the effect of GA on the 
disease, the pivotal study was extended by up to 11 months, 
with the GA versus placebo arms intact and blinded allow-
ing all patients to reach the 2-year time point (Johnson et al 
1998). Of the 215 patients completing the original study, 
203 entered the extension study and 194 completed it. The 
primary and secondary outcomes were the same. The relapse 
rates over the extended study were 1.34 and 1.98 for the GA 
and placebo groups, respectively (p = 0.002). The relapse-
free proportions were 33.6 and 24.6 (p = 0.035), and the 
median times to ﬁ  rst relapse were 287 and 198 (p = 0.057) 
for the GA and placebo groups, respectively. Overall status 
was deﬁ  ned by change in EDSS, with “improvement” or 
“worsening” deﬁ  ned as a one step decrease or increase in 
EDSS. While most patients had no change in EDSS over 
the extended study, some improved and others worsened. In 
the GA more improved than worsened (27.2% vs 18.4%), 
while in the placebo group, fewer improved than worsened 
(12.0% vs 31.2).
The open-label extension study
At the end of the extension study, all patients were invited 
to continue follow-up in an open-label study on GA, so that 
further clinical data could be collected. Most of the patients 
in the original double blind study, 208 out of 251 originally 
randomized (83%), chose to continue into the open label 
study, which is still ongoing. At the 8-year time point, 142 
patients (57% of the originally randomized and 68% of those 
who entered the open label phase) were still being followed 
(Johnson et al 2005). In order to analyze the effect of early 
treatment on MS, the patients were divided into two groups: 
group A were patients who had received GA from the begin-
ning and group B patients were initially randomized into the 
placebo group and subsequently were on open label GA, and 
their relapse rates and degree of disability ascertained. At 
the 8-year time point of the open label study, the annualized 
relapse rates were 0.43 in the group A and 0.52 in the group 
B patients, p = 0.0459. The overall proportion of patients 
with stable or improved neurological status (as measured 
by the EDSS) was 65.3 % in group A and 50.4% in group 
B (p = 0.0263).
Imaging studies
The European/Canadian (E/C) Imaging Study examined 
the effect of GA on MRI disease activity (Comi et al 2001), 
which was only done for a short period of time on patients 
at one of the 11 centers in the original pivotal study. In the 
E/C study, 239 RRMS patients were randomized to GA 
or placebo, and had monthly MRI scans and neurological 
examinations. The primary outcome was the number of 
enhancing lesions on T1 weighted images. There were a 
number of secondary outcome variables, including other 
measures of imaging activity and clinical events. The total 
number of enhancing lesions per subject over the 9 months 
of the study was 33.7 in the placebo group and 21.8 in the 
GA group (p < 0.001). The difference between the groups 
became statistically signiﬁ  cant 5 months into the study. The 
relapse rate in the treated group (0.51 per subject) was less 
than that in the placebo group (0.76 per subject), by 33% 
(p = 0.012). Other imaging outcomes were favorable to GA. 
In particular, the T2 lesion burden, as roughly measured by 
the mean total number of new T2 lesions, was 13.5 in the 
placebo and 9.4 in the active treatment groups, a 30% dif-
ference (p < 0.003).
In a substudy of the E/C Imaging Study, the proportion of 
initial T1-hypointense lesions evolving into permanent black 
holes, which represent permanently damaged tissue, was 
compared between the GA and placebo groups (Filippi et al 
2001). Of all T1-hypointense lesions, at 8 months, 15.6% in 
the GA group and 31.4% in the placebo group had evolved 
into black holes, thus suggesting a protective effect of GA Neuropsychiatric Disease and Treatment 2007:3(2) 262
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(p < 0.002). There was also a reduction in re-enhancing le-
sions by 59% when comparing the treated patients with those 
in the placebo group. 
Patients in this trial were recruited into an open-label 
extension phase lasting another 9 months, with the placebo 
subjects getting open label GA and the treatment subjects 
continuing on their medication (Wolinsky et al 2002). It was 
found that the number of enhancing lesions decreased by 54% 
in those who went from placebo to GA, and further decreased 
by 24.6% in those who continued on GA from the double-
blind to the open label phase (Wolinsky et al 2002). Interest-
ingly, the difference in T2 lesion burden persisted over the 
18 months of the study, suggesting that early treatment may 
preserve tissue, which was not regained in the switch from 
placebo to open label (Wolinsky et al 2002).
Imaging studies have been used to detect the extent of 
“neurodegeneration” by various surrogate measures. One 
possibility would be to use brain atrophy as a surrogate for the 
effects of degeneration. In a substudy of the original pivotal 
GA study, 27 patients were randomized to GA or placebo, 
and the number of enhancing T1 and T2 lesions, as well as 
brain parenchymal volume measured over 2 years. There 
was less atrophy in the GA group than in the placebo group 
(Ge et al 2000). In another study comparing two different 
methods of measuring brain atrophy, using data from the E-C 
study, there was a signiﬁ  cant decrease in the development of 
brain atrophy in the GA group compared with the placebo 
group, when using the more sensitive measure (Sormani 
et al 2004).
Magnetic resonance spectroscopy (MRS) measurements 
of brain chemistry have been very useful in understanding 
the pathogenesis of neurological diseases, and MS has been 
extensively studied. Various markers of neuronal and myelin 
structure have been measured and correlated with pathol-
ogy and disability. N-acetyl aspartate (NAA) is a marker of 
neuronal structure and axonal integrity. Its decrease in MS 
plaques indicates axonal injury, which may be only partly 
reversible (Arnold et al 2001). In a pilot study of the effect 
of GA on axonal injury in RRMS, 22 patients were recruited, 
18 of whom were treated with GA and 4 of whom declined 
treatment because of aversion to needles (Khan et al 2005). 
The patients were followed for 2 years. MRS measured NAA 
in a volume of interest (VOI) containing abnormal signal as 
well as in normal-appearing white matter (NAWM). In the 
GA group, the NAA-to-creatinine ratio (NAA/Cr, easily 
measured for technical reasons) had increased in the VOI 
by 10.7% in the treated group, while it had decreased by 
8.9% in the untreated group. Similarly, in the NAWM, the 
NAA/Cr was increased by 7.1% in the treated group, while 
it decreased by 8.2% in the untreated group. 
Anti-glatiramer antibodies
The issue of the generation of antibody to GA is an important 
one since antibodies can theoretically abrogate the beneﬁ  cial 
effect of the drug, as seems to be the case for interferon-beta 
and natalizumab therapy. Antibodies to GA acetate have 
been detected in the sera of patients treated with the drug 
(Brenner et al 2001). In this study, sera from 217 patients 
who participated in the treatment and placebo arms of several 
GA acetate trials were tested for antibodies to GA using an 
ELISA method. Antibodies to GA were of the IgG (more 
IgG1 than IgG2) but not IgM or IgE isotypes. They were 
detected in all of the active treatment patients but not in the 
placebo patients. The titers of these antibodies increased to a 
maximum at 3 months after initiation and slowly decreased 
thereafter. There was no change in antibody titers to myelin 
basic protein. Another study showed the presence of IgG4 
antibodies, detected by ELISA, in all 20 MS GA-treated 
patients, and in a minority of MS patients not treated with 
GA and normal controls (Farina et al 2002). There was no 
evidence of adverse effect of the antibodies, and indeed 
patients with higher antibody titers seemed to be more likely 
to be relapse-free (Brenner et al 2001). In vitro correlates of 
GA effect were observed either not affected or enhanced by 
antiGA antibodies in one study (Teitelbaum et al 2003) but 
not in another (Salama et al 2003). In the latter study it was 
proposed that some of the patients had antibodies that blocked 
the therapeutic effects but the in vitro immunologic endpoints 
were not necessarily measures of all of the mechanisms of 
action of GA, the clinical observations were not blinded and 
the number of patients was small.
Glatiramer acetate in primary 
progressive MS
A phase 3 trial of GA acetate in primary progressive MS 
(PPMS) was initiated in 1999 (Wolinsky 2004). The study 
randomized 943 patients to either GA or placebo for 36 
months, with a placebo-controlled extension phase. The 
primary endpoint was progression of disease as ascertained by 
a sustained (3 month) increase in EDSS by 1 point for baseline 
EDSS 3.0–5.0 (low tier) and by 0.5 point for baseline EDSS 
5.5–6.5 (high tier). Secondary endpoints included proportion of 
progression-free patients, changes in EDSS scores, number and 
volume of various lesions on MRI, black hole lesion burden, 
and brain volume loss. The study was discontinued early (at Neuropsychiatric Disease and Treatment 2007:3(2) 263
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the second interim analysis) because the progression rate in 
the placebo group was unexpectedly small: it was assumed 
that 50% of the low tier EDSS patients would progress in a 
year, but only 16.1% of patients in the placebo group did so 
(Wolinsky 2004). This rendered it impractical to demonstrate a 
clear treatment effect on the primary endpoint. However, there 
was a trend to reduced progression, signiﬁ  cantly decreased 
enhancing lesions and lower increases in T2 lesions in the 
treatment group compared with the placebo group (Wolinsky 
et al 2007). Thus, it may be premature to use glatiramer in 
PPMS, since the trial was unable to demonstrate beneﬁ  t in the 
target population and the long term safety of the drug was not 
demonstrated in this group, unlike RRMS. 
Systematic reviews 
and the Cochrane analysis
The efﬁ  cacy of GA in MS was examined in two meta-
analyses of clinical trials, one by the Cochrane Collaboration 
(Munari et al 2003) and the other by Boneschi et al (2003). 
In the Cochrane study, the results of three published studies 
were pooled (Bornstein et al 1987, 1991; Johnson et al 1995). 
In the Boneschi study, 3 studies, only one of which was in the 
Cochrane list, were analyzed together (Bornstein et al 1987; 
Johnson et al 1998; Comi et al 2001). The published studies 
were used in the Munari study, while the Boneschi study used 
the raw data from the original trials. The outcome variables 
examined in these two studies are shown in the Table 1.
The Munari study did not show an effect of GA on 
progression at 2 years, or change in disability score at fol-
low up, but did show a trend to a decrease in the number 
of patients with at least one exacerbation when a stratiﬁ  ed 
analysis was done, but not when the results were pooled. 
Relapse-free survival was better in the GA group, as were 
the number of hospitalizations and steroid courses at the end 
of follow up. The mean number of relapses showed no sig-
niﬁ  cant changes in years 1 and 2, but a decrease in year 3 in 
the GA group (Munari et al 2003). The study was criticized 
for using summary data rather than raw data, using results 
that mixed relapsing-remitting MS and “chronic progres-
sive” MS patients (these latter being a mixture of primary 
and secondary progressive MS), redeﬁ  nition of some of the 
outcome variables (conﬁ  rmed progression being deﬁ  ned at 
1 year rather than the more conventional 3 or 6 months), 
and choice of analysis (Caramanos and Arnold 2005; Comi 
et al 2005). In two of the studies incorporated in the Munari 
study, relapse numbers were measured. In the Bornstein study 
(Bornstein et al 1987), the number of relapses was 16 in the 
GA group and 64 in the placebo group, while in the Johnson 
study (Johnson et al 1995) the number of relapse per patient 
in 2 years was 1.19 in the GA group and 1.68 in the placebo 
group, a clear difference in favor of GA in both studies. No 
such beneﬁ  t was seen in the combined groups, however, 
which seems counterintuitive (Comi et al 2005).
The Boneschi meta-analysis showed signiﬁ  cant decreases 
in the annualized relapse rate, on-trial total number of 
relapses, time to ﬁ  rst relapse, and accumulated disability, 
favoring the GA group (Boneschi et al 2003). The different 
studies incorporated in the analysis had patients with a 
uniform diagnosis of relapsing-remitting MS but different 
baseline ages, disease durations, baseline EDSS, prestudy 
relapse rate, which were adjusted for.
Glatiramer mechanisms of action 
including neuroprotection models
Given the complexity of GA it is not surprising that there are 
likely several mechanisms of action. It was one of a number of 
compounds originally synthesized to help understand EAE, an 
animal model of MS. EAE was ﬁ  rst discovered by Rivers and 
Schwentker in an investigation of the inﬂ  ammatory demyelin-
ation in the brain which occurred after rabies vaccination and 
some viral infections such as measles (Rivers and Schwentker 
1935). These compounds contained polypeptides consisting of 
amino acids with stoichiometry similar to that of myelin basic 
protein, and were expected to provide well-deﬁ  ned antigens with 
which to induce EAE (Arnon 1996). It turned out that none of 
these compounds caused EAE in animals, and in fact, several 
inhibited it; copolymer 1 (the original name for GA) did this most 
Table 1 Outcome variables examined in the Munari and Bones-
chi meta-analyses
Munari et al  Boneschi et al 
Primary outcomes  Primary outcome 
Progression at 2 years  Annualized relapse rate 
Change in disability at 
follow up
Number of patients with 
at least one exacerbation  Secondary outcomes 
Relapse-free survival
  On-trial total number of relapses 
Secondary outcomes Time  to  ﬁ  rst relapse 
 Accumulated  disability 
Hospitalizations at end 
of follow up
Steroid courses at end 
of follow up
Additional outcomes
Mean number of relapsesNeuropsychiatric Disease and Treatment 2007:3(2) 264
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effectively. This provided a rationale for studying its effect on 
MS, as described above.
Several potential mechanisms of action have been 
suggested. These are not mutually exclusive, and all prob-
ably contribute to the drug’s efﬁ  cacy. Given the molecular 
resemblance of some of the components of the drug to frag-
ments of myelin basic protein, it is likely that molecular 
mimicry (in some sense) drives the effects of the drug on 
the disease process. 
The postulated steps in the immune reaction to myelin 
are as follows, in a very oversimpliﬁ  ed version. An activated 
T cell, sensitive to a myelin antigen (such as myelin basic 
protein (MBP), myelin oligodendrocyte glycoprotein (MOG), 
myelin associated glycoprotein (MAG) or others) penetrates 
the blood-brain barrier, and encounters an antigen-presenting 
cell (APC). The APC presents a peptide fragment from the 
relevant myelin antigen (perhaps in the process of turnover of 
myelin in the central nervous system), nestled in the groove 
of the major histocompatibility class II molecule (MHC-II), 
to the T cell, along with costimulatory ligands. The T cell 
receptor engages the peptide fragment nestled in the MHC-
II and the appropriate costimulatory ligands on the antigen 
presenting cell (APC) bind to the coreceptors on the T cell. 
The APC directs the phenotype of the T cells that are gener-
ated, with M1-type APCs stimulating T cells in a T helper-1 
(Th1) or “proinﬂ  ammatory” conﬁ  guration and M2-type 
APCs promoting Th2 or “anti-inﬂ  ammatory” T cells. In MS, 
the APCs seem to adopt an M1-phenotype, elaborating IL-12 
which activates the T cell into a Th1 state with production of 
Th1-type cytokines (such as IL-2, IFN-γ, TNFα). TNFα is 
also elaborated by APCs. These cytokines open up the blood-
brain barrier and allow ingress of other cellular and humoral 
inﬂ  ammatory mediators into the brain, eventually resulting in 
demyelination and injury to axons. There is strong evidence 
that in both MS and EAE Ig synthesis and deposition with 
complement activation contribute to demyelination (Raine 
et al 1999; Lucchinetti et al 2000).
The GA molecule most likely substitutes for the myelin 
peptide fragment in the APC and exerts its effects from there. 
The GA molecule is known to inhibit the proliferative T cell 
response to MBP (Teitelbaum et al 1992). The potential 
mechanisms of action include the following. 
(1) The GA molecule binds to the MHC-molecule on the 
APC so strongly that it displaces fragments of MBP from 
the APC which would otherwise have been presented to 
an appropriately sensitized T cell (Fridkis-Hareli et al 
1994). This binding occurs equally well with different 
MHC-II molecules, indicating a certain “promiscuity” 
in the choice of MHC-II haplotype to be used by GA 
(Fridkis-Hareli et al 1994). This may be one possible 
explanation of why GA prevents EAE induced by PLP 
in mice, although it is not known that GA displaces PLP 
from the MHC-II molecule (Teitelbaum et al 1996). It is 
not clear how relevant this mechanism of MBP antigen 
displacement is, however, since presumably APCs loaded 
with MBP are present in the brain, and subcutaneously 
injected GA will not have easy access to them.
(2) The GA-MHC-II complex binds to the T cell receptor 
of the T cell, thus preventing its activation by the MBP-
MHC-II complex on the APC. This would cause blockade 
of T cell receptors by a GA-MHC-II complex competing 
with an MBP-MHC-II complex. This may not happen 
centrally, since access of subcutaneously injected GA, 
complexing with an MHC-II molecule, does not easily 
have access to APCs located centrally. However, such 
an effect has been demonstrated in vitro (Aharoni et al 
1999).
(3) The GA-MHC-II complex binds to the T cell receptor 
and partially activates the T cell, inducing tolerance by 
an “altered peptide ligand” mechanism (Aharoni et al 
1999). GA thus induces a deviation from a pro-inﬂ  am-
matory Th-1 immune response to an anti-inﬂ  ammatory 
T helper-2 (Th-2) response, with secretion of the cyto-
kines IL-4, IL-5, IL-10, IL-13, and TGF-β, which some 
investigators consider a Th3 cytokine. Lymphocytes 
secreting anti-inﬂ  ammatory factors would explain the 
clinical improvement in animals with EAE who still have 
inﬂ  ammatory lesions, with the presence of lymphocytes, 
after treatment (Aharoni et al 2000; Lisak et al 1983). 
The quantity of anti-inﬂ  ammatory cytokines induced by 
the cross-reactivity of MBP and GA seems to be at the 
level of inducing increased cytokine secretion on a per 
cell basis (Farina et al 2001) rather than by induction of 
proliferation of lymphocytes. (Burns and Littleﬁ  eld 1991; 
Lisak et al 1983). This may be an alternative mechanism 
for how GA ameliorates PLP-induced EAE. That is, 
GA induces MBP reactive Th2 cells to release the same 
protective cytokines which in turn downregulate the re-
sponse of PLP-reactive Th1 cells. This has been called 
“bystander protection”. The therapeutic implications of 
this are evident (see below).
In EAE, Th-1 cells are thought to be mainly responsible 
for the disease state, since the disease can be transmitted to 
naïve syngeneic recipients by transfer of Th-1 cells, and reso-
lution of disease is associated with emergence of Th-2 cells. 
By analogy, Th-1 cells are thought to have a pathogenic role Neuropsychiatric Disease and Treatment 2007:3(2) 265
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in MS. GA has been shown to induce a deviation from a “pro-
inﬂ  ammatory” Th1 state in T cells to an “anti-inﬂ  ammatory” 
Th2 state, both in vitro and in vivo. Thus, when dendritic cells 
(DC), which are highly efﬁ  cient APC, are treated with GA, 
secretion of IL-12, a cytokine which causes Th-1 differentia-
tion of naïve Th cells, decreases in a dose-response manner. 
Naïve Th cells exposed to GA-treated DCs thus differentiate 
into Th-2 cells (Vieira et al 2003). EAE is suppressed in mice 
treated with Th-2 GA-induced T cells (Aharoni et al 1997). 
In a study of 8 MS patients treated with GA, GA-speciﬁ  c 
T cells were deviated to a Th-2 polarization (Qin et al 2000). 
This has been seen in other studies ( Duda et al 2000; Neuhaus 
et al 2000; Chen et al 2001).
There are other mechanisms which may also contribute 
to the therapeutic effect of GA in MS. As stated above, 
APCs activate antigen-speciﬁ  c T cells of either a Th1 or 
Th2 phenotype, depending on whether the APC has an M1 
or M2 phenotype (Kalinski et al 1999). It has been shown 
that GA inﬂ  uences APC towards an M1 (IL-12 secreting) or 
M2 (IL-10 secreting) phenotype (Hussien et al 2001; Farina 
et al 2005; Kim et al 2004; Weber et al 2004) which may in 
turn inﬂ  uence the resultant proportion of Th1 and Th2 lym-
phocytes reactive to GA and cross reacting myelin antigen 
speciﬁ  c T cells. There are reports of changes in function of 
monocytes/macrophages/microglia and dendritic cells in 
patients treated with GA (Balabanov et al 2001; Hussien 
et al 2001; Weber et al 2004) 
The lymphocytes of normal individuals and GA naive 
patients with MS respond to GA in vitro with a vigorous 
proliferative response whereas patients treated with GA lose 
this response. The loss of a proliferative response seems to be 
due to both clonal deletion and clonal anergy (Ragheb et al 
2001). This would reduce the number of potentially myelin 
reactive cells that also recognize GA which would be of po-
tential beneﬁ  t. Finally there is evidence that GA also can bind 
to MHC class 1 but not CD and thus inﬂ  uence CD8 (cytotoxic 
and immunosuppressive) T cells (Karandikar et al 2002).
Finally, as mentioned above, GA-speciﬁ  c T cells may have 
a neuroprotectant action by elaborating neurotrophic factors 
in addition to anti-inﬂ  ammatory cytokines. Activated T cells 
speciﬁ  c for myelin antigens have been shown to produce 
brain-derived neurotrophic factor (BDNF) (Kerschensteiner 
et al 1999) In a study of T cell lines obtained from GA-treated 
MS patients, 14% of the GA-reactive T cells (all Th-2) and 
smaller proportions of MBP- and tetanus toxoid (TT)-reac-
tive T cells were found to secrete BDNF (Kerschensteiner 
et al 1999; Chen et al 2003). GA-speciﬁ  c Th2 and Th1 cells 
both can secrete BDNF (Kipnis et al 2000; Ziemssen et al 
2002) as well as other neurotrophic factors although Th2 cells 
seem to secrete higher levels of these factors than Th1 cells. 
In addition both MBP- and GA-reactive T cells make nerve 
growth factor (NGF) and neurotrophin 4/5 (NT-4/5) (Kipnis 
et al 2000). It is of interest that in both GA treated animals
and naïve animals that receive GA reactive lymphocytes, 
neuroprotection can be demonstrated in both EAE (Aharoni 
et al 2000) as well as in models of optic nerve trauma 
(Kipnis et al 2000), retinal cell damage from glaucoma 
(Bakalash et al 2005) and degenerative diseases such as 
amyotrophic lateral sclerosis (Angelov et al 2003) and 
Parkinson’s disease (Benner et al 2004). More recently, 
glatiramer has shown hints of efﬁ  cacy in a mouse model of 
Alzheimer’s disease (Frenkel et al 2005), as well as some 
neuroprotectant effect in organophosphate neurotoxicity 
(Schori et al 2005).  However, whether the currently used 
regimen of GA in MS patients leads to the presence of BDNF-
secreting T cells in the brain is unknown.
Conclusion
Glatiramer acetate is a drug with beneﬁ  cial effects on the 
course of multiple sclerosis, reducing both relapse frequency 
and probably accumulation of deﬁ  cit over time. The drug also 
has beneﬁ  cial effects on MRI disease activity. Although the 
mechanisms of action are not known in detail, it is clear that they 
are multifactorial. There is a down-regulation of inﬂ  ammatory 
activity in the MS brain, as well as a neuroprotectant effect. In 
fact, the elaboration of BDNF by T cells may be useful in other 
disease states in which neurodegeneration plays a role. 
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